Table 3 KRAS mutation frequencies observed in carcinoma
From: KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay
primary carcinoma | recurrent carcinoma | carcinoma total | |||||||
|---|---|---|---|---|---|---|---|---|---|
n | mutated | % mutated | n | mutated | % mutated | n | mutated | % mutated | |
270 | 43 | 15.93 | 82 | 5 | 6.10 | 352 | 48 | 13.64 | |
histotype | |||||||||
serous | 177 | 17 | 9.60 | 69 | 4 | 5.80 | 246 | 21 | 8.54 |
endometroid | 34 | 4 | 11.76 | 5 | 0 | 0.00 | 39 | 4 | 10.26 |
mucinous | 25 | 15 | 60.00 | 5 | 1 | 20.00 | 30 | 16 | 53.33 |
clear cell | 19 | 5 | 26.32 | 2 | 0 | 0.00 | 21 | 5 | 23.81 |
undifferent. | 10 | 0 | 0.00 | 1 | 0 | 0.00 | 11 | 0 | 0.00 |
unknown | 5 | 2 | 40.00 | 5 | 2 | 40.00 | |||
age | |||||||||
≤ 50 | 72 | 16 | 22.22 | 31 | 4 | 12.90 | 103 | 20 | 19.42 |
> 50 | 198 | 27 | 13.64 | 51 | 1 | 1.96 | 249 | 28 | 11.24 |
grading | |||||||||
1 | 33 | 17 | 51.52 | 7 | 0 | 0.00 | 40 | 17 | 42.50 |
2 | 90 | 14 | 15.56 | 27 | 4 | 14.81 | 117 | 18 | 15.38 |
3 | 141 | 12 | 8.51 | 46 | 1 | 2.17 | 187 | 13 | 6.95 |
4 | 1 | 0 | 0.00 | 0 | 0 | 0.00 | 1 | 0 | 0.00 |
unknown | 5 | 0 | 0.00 | 2 | 0 | 0.00 | 7 | 0 | 0.00 |
FIGO stage | |||||||||
1 | 65 | 17 | 26.15 | 9 | 0 | 0.00 | 74 | 17 | 22.97 |
2 | 31 | 5 | 16.13 | 8 | 0 | 0.00 | 39 | 5 | 12.82 |
3 | 145 | 17 | 11.72 | 48 | 4 | 8.33 | 193 | 21 | 10.88 |
4 | 28 | 4 | 14.29 | 13 | 1 | 7.69 | 41 | 5 | 12.20 |
unknown | 1 | 0 | 0.00 | 4 | 0 | 0.00 | 5 | 0 | 0.00 |
pN | |||||||||
0 | 104 | 17 | 16.35 | 19 | 0 | 0.00 | 123 | 17 | 13.82 |
1 | 67 | 7 | 10.45 | 28 | 4 | 14.29 | 95 | 11 | 11.58 |
x | 99 | 19 | 19.19 | 35 | 1 | 2.86 | 134 | 20 | 14.93 |